| US 7,378,277 B2 | ||
| Methods and compositions for transforming dendritic cells and activating T cells | ||
| Patrick Hwu, Rockville, Md. (US); Mark Reeves, Grand Terrace, Calif. (US); and Steven A. Rosenberg, Potomac, Md. (US) | ||
| Assigned to The United States of America as represented by the Department of Health and Human Services, Washington, D.C. (US) | ||
| Filed on Jun. 26, 2003, as Appl. No. 10/607,327. | ||
| Application 10/607327 is a division of application No. 09/117764, filed on Jan. 07, 1999, granted, now 6,734,014. | ||
| Claims priority of provisional application 60/011433, filed on Feb. 08, 1996. | ||
| Prior Publication US 2004/0146492 A1, Jul. 29, 2004 | ||
| Int. Cl. C12N 15/00 (2006.01); C12N 15/74 (2006.01); C12N 5/00 (2006.01); C12N 5/08 (2006.01) | ||
| U.S. Cl. 435—455 [435/320.1; 435/325; 435/372; 435/377; 424/93.21; 424/93.71] | 12 Claims |
| 1. A method for detecting T cell mediated anti-cancer cell activity of a target antigenic peptide, comprising:
transforming a hematopoietic stem cell in vitro with a recombinant expression cassette comprising a nucleic acid encoding
the target antigenic peptide, and differentiating the transformed stem cell into a transformed dendritic cell;
contacting a T cell with the transformed dendritic cell, thereby providing an activated T cell, wherein the T cell and the
hematopoietic stem cell are from the same individual;
contacting a cancer cell expressing a protein comprising the target antigenic peptide with the activated T cell; and,
monitoring the effect of the activated T cell on the cancer cell, thereby detecting the anti cancer cell activity of the target
antigenic peptide.
|